Covid-19 and Mafld/Nafld: An Updated Review Publisher



Nowroozi A^{1, 2} ; Momtazmanesh S^{1, 2, 3} ; Rezaei N^{2, 3, 4} Show Affiliations
Source: Frontiers in Medicine Published:2023

Abstract

The COVID-19 pandemic is ongoing and places a substantial burden on healthcare systems worldwide. As we further shed light on different disease characteristics, we identify more and more groups of people at higher risk of poor COVID-19 outcomes. Metabolic-associated fatty liver disease (MAFLD) (previously non-alcoholic fatty liver disease or NAFLD) is a common metabolic disorder characterized by fat accumulation and liver fibrosis. Given its close correlation with metabolic syndrome, an established risk factor for severe COVID-19, it is necessary to investigate its interplay with the novel coronavirus. In this study, we review the available data on COVID-19 prognosis, treatment and prevention options in patients with MAFLD, and the effect that the disease and the pandemic have on MAFLD care. Furthermore, we point out the gaps in the current literature to accentuate the work that needs to be done to improve MAFLD care during the pandemic and beyond. Copyright © 2023 Nowroozi, Momtazmanesh and Rezaei.